Base de dados : MEDLINE
Pesquisa : D08.811.277.656.300.760.955.135 [Categoria DeCS]
Referências encontradas : 425 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 43 ir para página                         

  1 / 425 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365372
[Au] Autor:Fang X; Yu LS; Ma X; Xia RM; Jiang YH; Liu HX; Jing YY
[Ad] Endereço:Department of Otorhinolaryngology, People's Hospital of Peking University, Beijing 100044, China (now working at Human Anatomy Teaching and Research Department of Health Science Center of Peking University).
[Ti] Título:[Correlation between the changes of fibrinogen and the treatment effect of all-frequency sudden deafness].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(1):3-8, 2018 Jan 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To analyze the correlation between the changes of fibrinogen and the treatment effect of all-frequency sudden deafness, and to explore the individualized treatment strategy for the use of Batroxobin. Patients with all-frequency sudden deafness who were admitted to Department of Otorhinolaryngology, People's Hospital of Peking University, from January 2010 to September 2016 were selected. All patients were given standard treatment and regular use of Batroxobin. Value of fibrinogen on D1 (before treatment) / D3 / D7 (±1) and D14 (±2) were recorded, at the same time, the correlation between the changes of fibrinogen and prognosis of all-frequency sudden deafness by the audiograms of onset and after-treatment of all patients were analyzed. Independent -test was used to analyze normal distributed measurement data and chi square linear trend test was used to analyze the curative effect of different fibrinogen groups. A total of 148 patients were included, the outcomes were worst when the patient's fibrinogen was below 2 g/L or above 4 g/L before treatment, ineffective rate were both 50%. The fibrinogen was lowest when the treatment came to the third day. Normally, the patient's prognosis was best when this value waved between 0.7 and 0.9 g/L, with a total effective rate between 73.9% and 83.3%. The fibrinogen value of the 7th day was a good indicator of the outcome, and Fib7 value was significant lower in patients of effective group than ineffective ones ((1.25±0.37)g/L (1.38±0.35) g/L, =-0.27, =0.04). Patients found a best recovery when Fib7 was below 1 g/L, and the higher the Fib7 value, the higher the inefficiency (χ(2)=7.55, =0.01). Batroxobin showed safety during the treatment and found no complications. The change of fibrinogen in the process of all-frequency sudden deafness is closely related to the curative effect.
[Mh] Termos MeSH primário: Batroxobina/farmacologia
Fibrinogênio/efeitos dos fármacos
Fibrinolíticos/farmacologia
Perda Auditiva Súbita/sangue
Perda Auditiva Súbita/tratamento farmacológico
[Mh] Termos MeSH secundário: Distribuição de Qui-Quadrado
Fibrinogênio/análise
Testes Auditivos
Seres Humanos
Prognóstico
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 9001-32-5 (Fibrinogen); EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.01.002


  2 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28578650
[Au] Autor:Waheed H; Moin SF; Choudhary MI
[Ad] Endereço:Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, 75270-Karachi, Pakistan.
[Ti] Título:Snake Venom: From Deadly Toxins to Life-saving Therapeutics.
[So] Source:Curr Med Chem;24(17):1874-1891, 2017.
[Is] ISSN:1875-533X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Snakes are fascinating creatures and have been residents of this planet well before ancient humans dwelled the earth. Venomous snakes have been a figure of fear, and cause notable mortality throughout the world. The venom constitutes families of proteins and peptides with various isoforms that make it a cocktail of diverse molecules. These biomolecules are responsible for the disturbance in fundamental physiological systems of the envenomed victim, leading to morbidity which can lead to death if left untreated. Researchers have turned these life-threatening toxins into life-saving therapeutics via technological advancements. Since the development of captopril, the first drug that was derived from bradykininpotentiating peptide of Bothrops jararaca, to the disintegrins that have potent activity against certain types of cancers, snake venom components have shown great potential for the development of lead compounds for new drugs. There is a continuous development of new drugs from snake venom for coagulopathy and hemostasis to anti-cancer agents. In this review, we have focused on different snake venom proteins / peptides derived drugs that are in clinical use or in developmental stages till to date. Also, some commonly used snake venom derived diagnostic tools along with the recent updates in this exciting field are discussed.
[Mh] Termos MeSH primário: Venenos de Serpentes/química
[Mh] Termos MeSH secundário: Animais
Anticoagulantes/química
Anticoagulantes/metabolismo
Anticoagulantes/uso terapêutico
Batroxobina/química
Batroxobina/uso terapêutico
Coagulação Sanguínea/efeitos dos fármacos
Captopril/química
Captopril/uso terapêutico
Peptídeos/metabolismo
Peptídeos/farmacologia
Peptídeos/uso terapêutico
Venenos de Serpentes/metabolismo
Serpentes/metabolismo
Trombose/tratamento farmacológico
Trombose/patologia
Toxinas Biológicas/metabolismo
Toxinas Biológicas/farmacologia
Toxinas Biológicas/uso terapêutico
Tirosina/análogos & derivados
Tirosina/química
Tirosina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Peptides); 0 (Snake Venoms); 0 (Toxins, Biological); 42HK56048U (Tyrosine); 9G64RSX1XD (Captopril); EC 3.4.21.- (Batroxobin); GGX234SI5H (tirofiban)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.2174/0929867324666170605091546


  3 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28330422
[Au] Autor:Xu L; Liu L; Li X
[Ad] Endereço:a Department of Hemopurification, Affiliated Hospital of Jining Medical College , Jining , Shandong , China.
[Ti] Título:Bilateral rectal sheath hematomas after low-molecular weight heparin treatment in uremia.
[So] Source:Ren Fail;39(1):414-416, 2017 Nov.
[Is] ISSN:1525-6049
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Rectus sheath hematomas (RSHs) are uncommon. They are usually unilateral and rarely bilateral. In this paper, we report the first case of spontaneous bilateral RSHs in a uremic patient after the administration of the first dose of low-molecular weight heparin during hemodialysis. The most interesting aspect of this case is that the main symptom of RSH in our patient was urinary bladder irritation. We highlight the importance of the prompt diagnosis and management of this medical emergency.
[Mh] Termos MeSH primário: Anticoagulantes/efeitos adversos
Hematoma/induzido quimicamente
Heparina de Baixo Peso Molecular/efeitos adversos
Diálise Renal/efeitos adversos
Uremia/terapia
[Mh] Termos MeSH secundário: Dor Abdominal/diagnóstico
Dor Abdominal/etiologia
Administração Intravenosa
Anticoagulantes/administração & dosagem
Anticoagulantes/uso terapêutico
Batroxobina/administração & dosagem
Batroxobina/uso terapêutico
Transfusão de Componentes Sanguíneos
Hematoma/diagnóstico por imagem
Hematoma/terapia
Hemostáticos/administração & dosagem
Hemostáticos/uso terapêutico
Heparina de Baixo Peso Molecular/administração & dosagem
Heparina de Baixo Peso Molecular/uso terapêutico
Seres Humanos
Hiperpotassemia/sangue
Hiperpotassemia/terapia
Masculino
Meia-Idade
Plasma
Reto do Abdome/patologia
Diálise Renal/métodos
Trombose/prevenção & controle
Tomografia Computadorizada por Raios X
Ultrassonografia
Uremia/sangue
Doenças da Bexiga Urinária/diagnóstico por imagem
Doenças da Bexiga Urinária/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Hemostatics); 0 (Heparin, Low-Molecular-Weight); EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE
[do] DOI:10.1080/0886022X.2017.1305406


  4 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28161122
[Au] Autor:Kim OH; Cho KS; Seomun Y; Kim JT; Chung KH
[Ad] Endereço:Thrombosis and Vascular Biochemistry Lab., Dept of Biotechnology, College of Life Science, CHA University, CHA Bio-Complex, 335 Pangyo-ro, Seongnam-si 463-400, South Korea.
[Ti] Título:Acute and repeated dose (28 days) toxicity studies in rats and dogs of recombinant batroxobin, a snake venom thrombin-like enzyme expressed from Pichia pastoris.
[So] Source:Toxicon;129:153-163, 2017 Apr.
[Is] ISSN:1879-3150
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Recombinant batroxobin is a thrombin-like enzyme of Bothrops atrox moojeni venom. To evaluate its toxicological effect, it was highly expressed in Pichia pastorisand successfully purified to homogeneity from culture broth supernatant following Good Manufacturing Practice (GMP). The maximum tolerated dose of the recombinant batroxobin was examined in Sprague-Dawley (SD) rat and Beagle dogs following Good Laboratory Practice (GLP) regulations. The approximate lethal dose of recombinant batroxobin was 10 National Institute of Health (NIH) u/kg in male and female rats. Slight test substance-related effects were clearly in male and female dogs at more than 10 NIH u/kg. The maximum tolerated dose (MTD) was considered to be greater than 30 NIH u/kg in dogs. To investigate the repeated dose toxicity of batroxobin, the test item was intravenously administered to groups of SD rat and Beagle dog every day for 4 weeks. We observed that all animals survived the duration of the study without any effects on their mortality. There were no effects in both rats and dogs regarding their clinical signs, body weight, food consumption, ophthalmological examination, urinalysis, hematology, clinical chemistry, organ weightand gross post mortem examinations. The no adverse effect level (NOAEL) of recombinant batroxobin for both males and females is considered to be greater than 2.5 NIH u/kgin rats and 1 NIH u/kg in dogs, respectively. No toxic effects were noted in target organs. In conclusion, these results show a favorable preclinical profile and may contribute clinical development of recombinant batroxobin.
[Mh] Termos MeSH primário: Batroxobina/toxicidade
Venenos de Serpentes/química
Testes de Toxicidade Aguda
[Mh] Termos MeSH secundário: Animais
Peso Corporal
Cães
Relação Dose-Resposta a Droga
Feminino
Fermentação
Dose Letal Mediana
Masculino
Nível de Efeito Adverso não Observado
Tamanho do Órgão/efeitos dos fármacos
Pichia/metabolismo
Ratos
Ratos Sprague-Dawley
Proteínas Recombinantes/toxicidade
Trombina
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Recombinant Proteins); 0 (Snake Venoms); EC 3.4.21.- (Batroxobin); EC 3.4.21.5 (Thrombin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170206
[St] Status:MEDLINE


  5 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28019703
[Au] Autor:Vadalà G; Russo F; Musumeci M; D'Este M; Cattani C; Catanzaro G; Tirindelli MC; Lazzari L; Alini M; Giordano R; Denaro V
[Ad] Endereço:Department of Orthopaedic and Trauma Surgery, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
[Ti] Título:Clinically relevant hydrogel-based on hyaluronic acid and platelet rich plasma as a carrier for mesenchymal stem cells: Rheological and biological characterization.
[So] Source:J Orthop Res;35(10):2109-2116, 2017 Oct.
[Is] ISSN:1554-527X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intervertebral disc regeneration is quickly moving towards clinical applications. However, it is still missing an ideal injectable hydrogel to support mesenchymal stem cells (MSC) delivery. Herein, a new injectable hydrogel composed of platelet rich plasma (PRP) and hyaluronic acid (HA) blended with batroxobin (BTX) as gelling agent, was designed to generate a clinically relevant cell carrier for disc regeneration. PRP/HA/BTX blend was tested for rheological properties. Amplitude sweep, frequency sweep, and rotational measurements were performed and viscoelastic properties were evaluated. Human MSC encapsulated in PRP/HA/BTX hydrogel were cultured in both growing medium and medium with or without TGF-ß1 up to day 21. The amount of glycosaminoglycan was evaluated. Quantitative gene expression evaluation for collagen type II, aggrecan, and Sox 9 was also performed. Rheological tests showed that the hydrogel jellifies in 15 min 20°C and in 3 min at 37°C. Biological test showed that MSCs cultured in the hydrogel maintain high cell viability and proliferation. Human MSC within the hydrogel cultured with or without TGF-ß1 showed significantly higher GAG production compared to control medium. Moreover, MSCs in the hydrogel underwent differentiation to chondrocyte-like cells with TGF-ß1, as shown by histology and gene expression analysis. This novel hydrogel improves viability and proliferation of MSCs supporting the differentiation process toward chondrocyte-like cells. Rheology tests showed optimal gelation kinetics at room temperature for manipulation and faster gelation after transplantation (37°C). The clinical availability of all components of the hydrogel will allow a rapid translation of this regenerative approach into the clinical scenario. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:2109-2116, 2017.
[Mh] Termos MeSH primário: Batroxobina
Ácido Hialurônico
Hidrogéis/síntese química
Transplante de Células-Tronco Mesenquimais
Plasma Rico em Plaquetas
[Mh] Termos MeSH secundário: Voluntários Saudáveis
Seres Humanos
Reologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hydrogels); 9004-61-9 (Hyaluronic Acid); EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161227
[St] Status:MEDLINE
[do] DOI:10.1002/jor.23509


  6 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27769944
[Au] Autor:Seon GM; Lee MH; Kwon BJ; Kim MS; Koo MA; Kim D; Seomun Y; Kim JT; Park JC
[Ad] Endereço:Cellbiocontrol Laboratory, Department of Medical Engineering, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Re
[Ti] Título:Functional improvement of hemostatic dressing by addition of recombinant batroxobin.
[So] Source:Acta Biomater;48:175-185, 2017 Jan 15.
[Is] ISSN:1878-7568
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Although a number of natural materials have been used as hemostatic agents, many substances do not act quickly enough. Here, we created a novel dressings using collagen and chitosan with recombinant batroxobin (r-Bat) to promote faster and more effective hemostasis. We hypothesized that r-Bat would promote synergetic blood coagulation because it contains a blood coagulation active site different than those of collagen and chitosan. Our results suggest that each substances can maintain hemostatic properties while in the mixed dressings and that our novel hemostatic dressings promotes potent control of bleeding, as demonstrated by a whole blood assay and rat hemorrhage model. In a rat femoral artery model, the scaffold with a high r-Bat concentration more rapidly controlled excessive bleeding. This novel dressings has enormous possible for rapidly controlling bleeding and it improves upon the effect of collagen and chitosan used alone. Our novel r-Bat dressings is a possible candidate for improving preoperative care and displays promising properties as an absorbable agent in hemostasis. STATEMENT OF SIGNIFICANCE: Despite the excellent hemostatic properties of collagen and chitosan pads, they reported to brittle behavior and lack sufficient hemostatic effect within relevant time. Therefore, we created a novel pad using collagen and chitosan with recombinant batroxobin (r-Bat). r-Bat acts as a thrombin-like enzyme in the coagulation cascade. Specifically, r-Bat, in contrast to thrombin, only splits fibrinopeptide A off and does not influence other hemostatic factors or cells, which makes it clinically useful as a stable hemostatic agent. Also the materials in the pad have synergetic effect because they have different hemostatic mechanisms in the coagulation cascade. This report propose the novel hemostatic pad isreasonable that a great potential for excessive bleeding injury and improve effects of natural substance hemostatic pad.
[Mh] Termos MeSH primário: Bandagens
Batroxobina/farmacologia
Hemostáticos/farmacologia
Proteínas Recombinantes/farmacologia
[Mh] Termos MeSH secundário: Animais
Coagulação Sanguínea/efeitos dos fármacos
Bovinos
Modelos Animais de Doenças
Artéria Femoral/efeitos dos fármacos
Artéria Femoral/patologia
Fibrinogênio/metabolismo
Hemorragia/patologia
Fígado/efeitos dos fármacos
Fígado/patologia
Microscopia Eletrônica de Varredura
Nefelometria e Turbidimetria
Ativação Plaquetária/efeitos dos fármacos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hemostatics); 0 (Recombinant Proteins); 9001-32-5 (Fibrinogen); EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  7 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27679398
[Au] Autor:Li D; Tong L; Kawano H; Liu N; Liu L; Li HP
[Ad] Endereço:Department of Human Anatomy, College of Basic Medical Sciences, China Medical University, Shenyang, China.
[Ti] Título:Protective effects of batroxobin on a nigrostriatal pathway injury in mice.
[So] Source:Brain Res Bull;127:195-201, 2016 Oct.
[Is] ISSN:1873-2747
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Traumatic brain injury triggers a series of damaged processes, such as neuronal death and apoptosis, inflammation and scar formation, which contribute to evolution of brain injury. The present study investigated the neuroprotective effects of batroxobin, a drug widely used clinically for ischemia, in a nigrostriatal pathway injury model. Mice subjected to the nigrostriatal pathway injury were injected with batroxobin (30 BU/kg) or vehicle immediately after injury. The behavioral studies showed that batroxobin could improve the motor function in injured mice in long term. Batroxobin also reduced neuronal apoptosis and inflammation at the acute stage. Moreover, administration of batroxobin attenuated the scar formation and reduced the lesion size at 4 and 14days after brain injury. These results suggest that batroxobin has beneficial effects on the nigrostriatal pathway injury, indicating a potential clinical application.
[Mh] Termos MeSH primário: Batroxobina/farmacologia
Corpo Estriado/efeitos dos fármacos
Corpo Estriado/lesões
Fármacos Neuroprotetores/farmacologia
Substância Negra/efeitos dos fármacos
Substância Negra/lesões
[Mh] Termos MeSH secundário: Animais
Apoptose/efeitos dos fármacos
Apoptose/fisiologia
Cicatriz/tratamento farmacológico
Cicatriz/imunologia
Cicatriz/patologia
Corpo Estriado/imunologia
Corpo Estriado/patologia
Modelos Animais de Doenças
Masculino
Camundongos
Atividade Motora/efeitos dos fármacos
Atividade Motora/fisiologia
Vias Neurais/efeitos dos fármacos
Vias Neurais/imunologia
Vias Neurais/lesões
Vias Neurais/patologia
Distribuição Aleatória
Substância Negra/imunologia
Substância Negra/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neuroprotective Agents); EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160929
[St] Status:MEDLINE


  8 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27433096
[Au] Autor:Wang T; Wang DN; Liu WT; Zheng ZQ; Chen X; Fang WL; Li S; Liang L; Wang BM
[Ad] Endereço:Tao Wang, Dan-Na Wang, Wen-Tian Liu, Zhong-Qing Zheng, Xin Chen, Wei-Li Fang, Shu Li, Li Liang, Bang-Mao Wang, Department of Gastroenterology, Tianjin Medical University General Hospital, Tianjin 300052, China.
[Ti] Título:Hemostatic effect of topical hemocoagulase spray in digestive endoscopy.
[So] Source:World J Gastroenterol;22(25):5831-6, 2016 Jul 07.
[Is] ISSN:2219-2840
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIM: To evaluate the hemostatic effect of topical hemocoagulase spray in digestive endoscopy. METHODS: Eighty-nine patients who developed oozing bleeding during endoscopic treatment from September 2014 to October 2014 at Center for Digestive Endoscopy, Tianjin Medical University General Hospital were randomly divided into either a study group (n = 39) or a control group (n = 50). The study group was given topical hemocoagulase spray intraoperatively, while the control group was given traditional 8% norepinephrine spray. Hemostatic efficacy was compared between the two groups. Bleeding site, wound cleanliness and perforation were recorded, and the rates of perforation and late bleeding were compared. RESULTS: Successful hemostasis was achieved in 39 (100%) patients of the study group and in 47 (94.0%) patients of the control group, and there was no significant difference in the rate of successful hemostasis between the two groups. Compared with the control group, after topical hemocoagulase spray in the study group, the surgical field was clearer, the bleeding site was more easily identified, and the wound was cleaner. There was no significant difference in the rate of perforation between the study and control groups (16.7% vs 35.0%, P = 0.477), but the rates of late bleeding (0% vs 15.8%, P = 0.048) and overall complications (P = 0.032) were significantly lower in the study group. CONCLUSION: Topical hemocoagulase spray has a definite hemostatic effect for oozing bleeding in digestive endoscopy, and this method is convenient, safe, and reliable. It is expected to become a new method for endoscopic hemostasis.
[Mh] Termos MeSH primário: Batroxobina/uso terapêutico
Ressecção Endoscópica de Mucosa/métodos
Hemostase Endoscópica/métodos
Hemostáticos/uso terapêutico
[Mh] Termos MeSH secundário: Administração Tópica
Endoscopia do Sistema Digestório/métodos
Feminino
Seres Humanos
Perfuração Intestinal/epidemiologia
Masculino
Meia-Idade
Norepinefrina/uso terapêutico
Complicações Pós-Operatórias/epidemiologia
Hemorragia Pós-Operatória/epidemiologia
Resultado do Tratamento
Vasoconstritores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Hemostatics); 0 (Vasoconstrictor Agents); EC 3.4.21.- (Batroxobin); X4W3ENH1CV (Norepinephrine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170412
[Lr] Data última revisão:
170412
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160720
[St] Status:MEDLINE
[do] DOI:10.3748/wjg.v22.i25.5831


  9 / 425 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27197462
[Au] Autor:Zhang C; Liu Y; Liu G
[Ti] Título:[Hypofibrinogenemia caused by hemocoagulase after endoscopic sinus surgery: a case report].
[So] Source:Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;30(1):70-1, 2016 Jan.
[Is] ISSN:1001-1781
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:A 61 year-old male patient, plasma fibrinogen level was 2.98 g/L, endoscopic sinus surgery was performed under general anesthesia for polypoid of uncinate process with mycotic maxillary sinusitis. Hemocoagulase were given in pre- and post-operative for treatment. The patient was found postoperative drain blood continuously since 3 days after surgery, when the dose of hemocoagulase reach 26 KU, and fibrinogen determined in Plasma was 0.48 g/L. Coagulation returned to normal and nasal bleeding stopped after discontinuation of the hemocoagulase and supplement with fibrinogen.
[Mh] Termos MeSH primário: Batroxobina/efeitos adversos
Transtornos da Coagulação Sanguínea/induzido quimicamente
Endoscopia/efeitos adversos
Fibrinogênio/análise
Procedimentos Cirúrgicos Nasais/efeitos adversos
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Meia-Idade
Seios Paranasais/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
9001-32-5 (Fibrinogen); EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:160520
[Lr] Data última revisão:
160520
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160521
[St] Status:MEDLINE


  10 / 425 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26636421
[Au] Autor:Xu YY; Ma XH; Zhang SJ
[Ti] Título:Hemocoagulase agkistrodon-induced anaphylactic shock: A case report and literature review.
[So] Source:Int J Clin Pharmacol Ther;54(2):129-34, 2016 Feb.
[Is] ISSN:0946-1965
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Hemocoagulase agkistrodon for injection is the national first-class new drug of China with good hemostatic function and safety for capillary hemorrhage in abdominal incision of surgical patients. Adverse drug reactions (ADRs) to hemocoagulase agkistrodon are rarely reported. In this paper, we describe a case of a 41-year-old woman who developed anaphylactic shock attributed to hemocoagulase agkistrodon before colon cancer surgery. Based on the Naranjo ADR probability score, a "probable" cause and effect relationship existed for this case. Although the cause of anaphylactic reaction (hemocoagulase or excipient) and exact mechanism of hemocoagulase agkistrodon-induced anaphylactic reaction are unknown, attention should be drawn to potential ADRs in clinical use.
[Mh] Termos MeSH primário: Anafilaxia/etiologia
Batroxobina/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Agkistrodon
Animais
Feminino
Seres Humanos
Injeções
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
EC 3.4.21.- (Batroxobin)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:160127
[Lr] Data última revisão:
160127
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151205
[St] Status:MEDLINE
[do] DOI:10.5414/CP202296



página 1 de 43 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde